SHAH MAHENDRA 4
4 · Verona Pharma plc · Filed Aug 5, 2025
Insider Transaction Report
Form 4
SHAH MAHENDRA
Director
Transactions
- Sale
Ordinary Shares
2025-08-01$13.14/sh−3,608$47,422→ 93,472 total - Exercise/Conversion
Restricted Stock Units
2025-08-01−24,000→ 72,000 total→ Ordinary Shares (24,000 underlying) - Exercise/Conversion
Ordinary Shares
2025-08-01+24,000→ 97,080 total
Footnotes (6)
- [F1]Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
- [F2]The sale reported in the Form 4 represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the Reporting Person's tax withholding obligation upon the vesting of the restricted stock units ("RSUs").
- [F3]The price reported represents the sale price of the ADSs divided by eight (8).
- [F4]Consists of 93,472 Ordinary Shares represented by 11,684 ADSs.
- [F5]Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.
- [F6]The RSUs vest as to 25% of the total shares on each of August 1, 2025, November 1, 2025, February 1, 2026 and May 1, 2026 subject to the Reporting Person's continued service to the Issuer on each vesting date.